MedTrace Logo

Psilocybin-Assisted Therapy for Intergenerational Trauma

NCT06899165 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-08

No results posted yet for this study

Summary

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders.

The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Conditions

Interventions

DRUG

Psilocybin

Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists

BEHAVIORAL

Integration sessions

weekly integration sessions (therapy) for 6 weeks

Sponsors & Collaborators

  • Rachel Yehuda

    lead OTHER

Principal Investigators

  • Rachel Yehuda, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2029-05-31
Completion
2030-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06899165 on ClinicalTrials.gov